The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -175,351 | -169,137 | -165,361 | -353,348 |
| Share-based compensation | - | 0 | 0 | 0 |
| Interest expense on loan payable | - | - | 0 | 0 |
| Accretion to redemption value on convertible notes | - | 0 | 0 | 0 |
| Non-cash interest on convertible notes | 18,082 | 18,484 | 18,483 | 36,365 |
| Prepaid expenses and other current assets | -6,504 | -7,277 | 19,421 | -22,476 |
| Accounts payable | 34,274 | -975 | -49 | -1,057 |
| Accrued compensation | 116,161 | 119,099 | 123,111 | 244,346 |
| Accrued expenses and other | -3,220 | -2,887 | 21,415 | -10,218 |
| Net cash used in operating activities | -3,550 | -28,139 | -21,822 | -61,436 |
| Proceeds from the issuance of loans payable | - | 0 | 0 | 0 |
| Payments on loan payables | - | 0 | - | - |
| Net cash provided by financing activities | - | 0 | 0 | 0 |
| Net change in cash and cash equivalents | -3,550 | -28,139 | -21,822 | -61,436 |
| Cash and cash equivalents, beginning of period | 3,622 | 31,761 | 115,019 | - |
| Cash and cash equivalents, end of period | 72 | 3,622 | 31,761 | - |
Mosaic ImmunoEngineering Inc. (CPMV)
Mosaic ImmunoEngineering Inc. (CPMV)